Market Cap : 936.16 M | Enterprise Value : 860.33 M | PE Ratio : At Loss | PB Ratio : |
---|
NYSE:MYOV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:MYOV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Myovant Sciences's revenue per share for the three months ended in Mar. 2022 was $0.61. Myovant Sciences's revenue per share for the trailing twelve months (TTM) ended in Mar. 2022 was $2.48.
During the past 12 months, the average Revenue Per Share Growth Rate of Myovant Sciences was 276.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Myovant Sciences's Revenue per Share or its related term are showing as below:
The historical data trend for Myovant Sciences's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Myovant Sciences's Revenue Per Share for the fiscal year that ended in Mar. 2022 is calculated as
Revenue Per Share (A: Mar. 2022 ) | = | Revenue (A: Mar. 2022 ) | / | Shares Outstanding (Diluted Average) (A: Mar. 2022 ) |
= | 230.972 | / | 92.975 | |
= | 2.48 |
Myovant Sciences's Revenue Per Share for the quarter that ended in Mar. 2022 is calculated as
Revenue Per Share (Q: Mar. 2022 ) | = | Revenue (Q: Mar. 2022 ) | / | Shares Outstanding (Diluted Average) (Q: Mar. 2022 ) |
= | 57.567 | / | 94.356 | |
= | 0.61 |
Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.48
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Thank you for viewing the detailed overview of Myovant Sciences's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Potter Myrtle S | director | 10 FINDERNE AVE BRIDGEWATER NJ 08807 |
Guinan Mark | director | C/O QUEST DIAGNOSTICS 500 PLAZA DRIVE SECAUCUS NJ 07094 |
Arjona Ferreira Juan Camilo | officer: Chief Medical Officer | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
Curran Terrie | director | C/O MYOVANT SCIENCES INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018 |
Gulfo Adele M. | director | ONE NEENAH CENTER, 4TH FLOOR P.O. BOX 669 NEENAH WI 54957 |
Sebelius Kathleen | director | C/O DERMIRA, INC. 275 MIDDLEFIELD ROAD, SUITE 150 MENLO PARK CA 94025 |
Lang Matthew | officer: General Counsel & Corp. Secy. | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
Sumitomo Chemical Co., Ltd. | 10 percent owner | 27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260 |
Sumitovant Biopharma Ltd. | 10 percent owner | C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018 |
Dainippon Sumitomo Pharma Co Ltd | 10 percent owner | 60 WALL STREET NEW YORK NY 10005 |
Seely Lynn | director, officer: Principal Executive Officer | 501 2ND STREET SUITE 211 SAN FRANCISCO CA 94107 |
Sablich Kim | officer: Chief Commercial Officer | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005 |
Nomura Hiroshi | director | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005 |
Roivant Sciences Ltd. | 10 percent owner | CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11 |
Torti Frank | director | 2855 SAND HILL ROAD MENLO PARK CA 94025 |
From GuruFocus
Other Sources
By Zacks 2021-05-11
By Seekingalpha 2021-02-11
By Zacks 2020-12-16
By Zacks 2020-12-29
By Seekingalpha 2021-10-26
By Fool 2020-12-28
By Seekingalpha 2021-01-19
By Seekingalpha 2022-01-02
By Seekingalpha 2021-06-02
By Zacks 2020-12-29
By Fool 2021-07-28
By tipranks.com 2022-02-16
By Seekingalpha 2021-05-24
By Zacks 2021-10-29